The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its ...
The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to ...
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
locally advanced or metastatic pheochromocytoma and paraganglioma (PPGL). A recent review in Cancers from Dr. Camilo Jimenez and colleagues at the MD Anderson Cancer Center in Houston, Texas ...
Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...
MEN type 2B is a very rare disorder and can cause medullary thyroid cancer, pheochromocytoma, and lesions on the tongue and lips (mucosal neuromas). Familial paraganglioma-pheochromocytoma syndrome is ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback